Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lyell Immunopharma Inc (Lyell) is a biotechnology company developing cell-based immunotherapies for solid tumors and other cancers. It provides effective cell therapy is the profound understanding of the identity, fate, and function of cells to create living medicines. The company focuses on controlling and improving the differentiation and functionality of T cells armed with TCRs (T-cell receptor), CARs (chimeric antigen receptor), and other targeting modalities. Lyell 's effective cell therapy is the deep and profound understanding of the identity, fate and function of cells to create living medicines. The company operates an office in Seattle, Washington, the US. Lyell is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
201 Haskins Way, Suite 301, South San Francisco, California, 94080
Website
lyell.com
Telephone
1 650 6950677
No of Employees
224
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LYEL (NASD)
Revenue (2022)
$130,000
-99.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-28.1%
(2022 vs 2021)
Market Cap*
$594.0M
Net Profit Margin (2022)
XYZ
-83,365.7%
(2022 vs 2021)
* As of and is in US$
Lyell Immunopharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| CAR Cell Therapies |
| TIL Cell Therapies |
| TCR Cell Therapies |
Competitor Comparison
| Key Parameters | Lyell Immunopharma Inc | Sangamo Therapeutics Inc | Pharmaceutical & Medicinal Public Company | Allogene Therapeutics Inc | Clondalkin Pharma & Healthcare (Northampton) Ltd. |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Vietnam | United States of America | United Kingdom |
| City | South San Francisco | Richmond | Ho Chi Minh | South San Francisco | Northampton |
| State/Province | California | California | - | California | England |
| No. of Employees | 224 | 405 | 591 | 232 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rick Klausner, M.D. | Chairman | Executive Board | - | - |
| Richard Klausner | Chairman | Executive Board | 2018 | 71 |
| Lynn Seely, MD | Director; Chief Executive Officer; President | Executive Board | 2021 | 64 |
| Elizabeth Homans | Chief Executive Officer; Director | Senior Management | 2018 | 57 |
| Charles Newton | Chief Financial Officer | Senior Management | - | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer